Previous close | 281.79 |
Open | 280.17 |
Bid | 285.55 x 900 |
Ask | 288.20 x 800 |
Day's range | 279.46 - 287.86 |
52-week range | 176.36 - 293.17 |
Volume | |
Avg. volume | 1,769,017 |
Market cap | 73.484B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 29.71 |
EPS (TTM) | 9.67 |
Earnings date | 27 Jul 2022 - 01 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 293.51 |
If you hold on to a promising growth stock for five years, you should expect to accumulate some decent gains over that time. Investing in just the S&P 500 would have resulted in a nearly 60% increase in value -- and that's even after factoring in this year's bearish market. Five years ago, Vertex Pharmaceuticals (NASDAQ: VRTX) was coming off a year when its revenue soared by 65% to $1.7 billion.
Is a recession coming? Ark Invest CEO Cathie Wood thinks that one has already arrived. Economists surveyed by The Wall Street Journal put the odds of a recession over the next 12 months at 44%. Federal Reserve chairman Jerome Powell recently said that a recession is "a possibility," although the Fed is trying to avoid causing one with its interest rate hikes.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $280.35, marking a +1.51% move from the previous day.